Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients in placebo and active group

From: Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid

  Placebo group
(n= 20)
Active group
(n= 20)
Demographic variables   
   Age, years 45.5 (0.5, 49) 47 (33.5, 50)
   Height, cm 156.6 (151.5, 158.5) 157.0 (151.9, 160.4)
   Weight, kg 50.3 (44.1, 63.5) 50.5 (46.6, 56.9)
   Menopausal, number (%) 13 (65%) 11 (55%)
   Duration of menopause, years 2 (0-6.5) 0.5 (0-3)
Clinical variables   
   Disease duration, years 12.7 (8.8, 18.8) 13.4 (9.6, 18.8)
   SLEDAI score 2.0 (0, 2.8) 2.0 (0, 3)
   SDI score 1 (0.3, 1) 1 (0, 2)
   Anti-ds DNA 31.5 (0-188) 0 (0-81)
   C3, mg/L 0.92 (0.71, 1.12) 0.85 (0.65,0.97)
   C4, mg/L 0.22 (0.16, 0.26) 0.18 (0.10, 0.23)
   CRP, mg/L 1.1 (0.5-5.5) 0.5 (0.5-1.7)
   Creatinine clearance, ml/min 74 (46.9, 108.8) 73.0 (55.5, 86.5)
   Ever had lupus nephritis, number (%) 17 (85) 13 (65)
Use of glucocorticoids   
   Duration of glucocorticoids, years 12.7 (8.5, 18.8) 13.4 (9.8, 20.1)
   Current dose of prednisolone, mg/day 5 (5, 7.5) 5 (5, 7.5)
   Highest dose of prednisolone, mg/day 40 (30, 40) 40 (30, 50)
   Cumulative dose of glucocorticoids, mg 33, 177.7 (22, 642.6, 44, 473.0) 32, 329.3 (20, 448.9, 43, 385.1)
T-score of DXA   
   Lumbar spine -1.45 (-1.78, -0.93) -1.10 (-1.65, -0.5)
   Hip -1.15 (-1.58, -0.5) -1.15 (-1.75, -0.7)
   Osteoporosis, number (%)   
   Lumbar spine 2(10) 2 (10)
   Hip 0 (0) 1 (5)
Osteopenia, number (%)   
   Lumbar spine 13 (65) 11 (55)
   Hip 12 (60) 11(55)
  1. Data are expressed in median (IQR), unless specified otherwise. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; anti-ds DNA, anti-double-stranded DNA; C3, C4, complement 3, 4; CRP, C-reactive protein; DXA, dual energy x-ray absorptiometry; IQR, interquartile range.
  2. Creatinine clearance measurements were done only in those with active nephritis, as defined as 24-urine protein > 0.5 g.